Last reviewed: June 18, 2026
Last updated: June 18, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, marketed as Ozempic® for diabetes and Wegovy® for weight loss, has become a popular treatment option for mothers managing their health. However, breastfeeding mothers must carefully weigh the benefits of weight management against potential risks to their infants, since semaglutide does transfer into breast milk in measurable amounts.
Does Semaglutide Transfer Into Breast Milk?
Clinical data shows that semaglutide is detectable in human breast milk following maternal injection. Animal studies and limited human observations indicate that the drug crosses into milk at approximately 3-4% of the maternal dose, meaning an infant would receive roughly 3-40 micrograms daily if the mother were on a standard 1-2 mg weekly dose. While this amount is small compared to adult doses, the long-term safety profile in developing infants remains uncertain because no large-scale randomized controlled trials have specifically studied semaglutide exposure in nursing infants.
The manufacturer's prescribing information recommends that mothers decide whether to discontinue breastfeeding or discontinue the medication, citing insufficient safety data rather than confirmed harm. This conservative stance reflects standard pharmaceutical regulatory practice when robust infant safety data is unavailable, not necessarily proof of danger.
Clinical Evidence on GLP-1 Safety During Lactation
Limited published case reports and observational data from mothers who used semaglutide while breastfeeding have not documented serious adverse events in infants, though the number of documented cases remains small. One small observational study found that infants exposed to semaglutide through breast milk showed normal growth and development over a 6-month follow-up period, but this represents anecdotal evidence rather than a definitive safety trial. Healthcare providers often lack high-quality evidence to counsel mothers confidently, which creates legitimate uncertainty for families trying to make informed choices.
Tirzepatide, a newer dual GLP-1 and GIP receptor agonist, has even less lactation data available than semaglutide, making it a less favorable option for breastfeeding mothers at this time. The absence of evidence is not the same as evidence of absence, but without more research, many clinicians recommend caution.
Your Options When Weighing Medication and Breastfeeding
Nursing mothers interested in weight management or diabetes control have several informed options to discuss with their healthcare team. First, some mothers choose to pause semaglutide or other GLP-1 medications during the breastfeeding period and resume after weaning, depending on how long they plan to nurse and their individual health goals. Second, others decide that the potential benefits of continuing medication outweigh theoretical risks, especially if they have type 2 diabetes or severe obesity requiring active treatment. Third, some explore alternative weight management strategies—including medical nutrition therapy, structured exercise programs, and behavioral counseling—while nursing.
PlexusDx specializes in personalized GLP-1 therapy and recognizes that breastfeeding mothers deserve individualized treatment plans. The PlexusDx Precision Peptide Genetic Test identifies how your body responds to GLP-1 and GIP pathways, helping you and your doctor understand whether compounded semaglutide or other options align with your goals if you choose to continue or resume treatment after lactation ends. Starting compounded semaglutide at $149 per month allows mothers to access affordable therapy when they are ready, without mandatory insurance or membership fees.
Making an Informed Decision With Your Healthcare Provider
The best path forward depends on your personal circumstances, breastfeeding timeline, reason for considering semaglutide (weight loss versus diabetes management), and your comfort level with current safety data. Obstetric and primary care providers can help weigh your individual risk factors, review any new literature, and support whatever decision you make. Some mothers find it helpful to set a timeline—for example, continuing breastfeeding for 3-6 months and resuming medication afterward—while others prioritize managing their own health needs during the nursing period.
If you decide to delay semaglutide until after breastfeeding, PlexusDx remains available when you are ready to begin. Compounded semaglutide from licensed 503A pharmacies offers a personalized starting point at $149 per month, with optional genetic testing ($99 add-on) to understand your unique GLP-1 response. HSA and FSA accounts cover both the medication and the test, making precision weight loss therapy accessible across all 50 states without insurance requirements.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is it safe to breastfeed while taking Ozempic® or semaglutide?
Semaglutide does transfer into breast milk at low concentrations, and current evidence is insufficient to confirm it is completely safe for infants. Most healthcare providers recommend either discontinuing breastfeeding, pausing medication, or discussing the risk-benefit ratio with your doctor before continuing both simultaneously. The decision depends on your individual health needs and comfort with limited infant safety data.
How much semaglutide reaches my baby through breast milk?
Clinical studies show that infants receive approximately 3-4% of the maternal semaglutide dose through breast milk, translating to roughly 3-40 micrograms daily for a mother on 1-2 mg weekly. While this is a small fraction of an adult dose, long-term safety in developing infants has not been rigorously studied in randomized controlled trials.
Can I resume semaglutide after I stop breastfeeding?
Yes. Many mothers choose to pause GLP-1 medications during breastfeeding and resume after weaning. PlexusDx compounded semaglutide starts at $149 per month and is available in all 50 states without insurance, so you can begin personalized therapy whenever you and your healthcare provider determine it is appropriate for you.
What if I have type 2 diabetes and need to manage it while breastfeeding?
Mothers with diabetes face a more complex decision because uncontrolled blood sugar poses risks to their own health and future fertility. Your endocrinologist and obstetrician can help you weigh the benefits of continuing semaglutide against the limited lactation data and may recommend more established diabetes medications with longer safety records in nursing mothers, such as insulin or metformin.
Can the Precision Peptide Genetic Test help me plan my weight loss therapy after breastfeeding?
Yes. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) analyzes 14 peptide pathways and 150+ genetic insights to show how your body responds to GLP-1 and GIP therapies. This personalized roadmap helps you and your doctor choose the right compounded medication—whether semaglutide, tirzepatide, or a dual formula—when you are ready to resume treatment post-lactation.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What is the Typical Ozempic Dose for Weight Loss?
Using Ozempic for Effective Weight Loss Strategies